Physician profile
Peter S Pang
NPI 1821029554
$22,534.25
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,228 · 2020: $2,030 · 2022: $9,236 · 2024: $4,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,040.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $6,857.53 | 2019 | |
| Eagle Pharmaceuticals, INC. | $4,551.38 | 2022 | |
| Incyte Corporation | $3,550.00 | 2024 | |
| Roche Diagnostics International LTD | $3,500.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $2,400.34 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $1,185.00 | 2022 | |
| Chugai Pharmaceutical Co., LTD. | $490.00 | 2024 |
4 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.